- Researchers investigated a novel combination treatment involving an oncolytic virus and immunotherapy for recurrent glioblastoma.
- The treatment increased survival rates from 6–8 months to 12.5 months.
- Further studies are needed before the treatment can be used on patients.
Glioblastoma is the most
Around
The current standard of care for newly diagnosed patients involves surgery and chemoradiotherapy. However, the condition recurs in many of these patients after treatment.
On average, patients with glioblastoma survive for 6-8 months after their first diagnosis, and the 5-year survival rate is 6.8%.
Research into effective treatments is essential for improving outcomes and survival rates for patients with glioblastoma.
Recently, researchers investigated the safety and effectiveness of a new therapy that combines an oncolytic virus — a genetically-modified virus that targets and kills cancer cells — and intravenous immunotherapy.
The treatment eradicated tumors in certain patients and increased average survival from 6-8 months to 12.5 months.
Dr. Jay-Jiguang Zhu, a neuro-oncologist with McGovern Medical School at UTHealth Houston, not involved in the study, told Medical News Today:
“[This study] shows to the world that such a combination can be done, and it is safe. It is exciting and significant work! Also, given the current dosing and regimen, it is likely to help patients with glioblastoma. But hopefully further improvement of this regimen can provide more benefit to glioblastoma patients.”
The study was published in
Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that works by blocking certain proteins that…
Read the full article here